Literature DB >> 21942285

Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression.

Prashant Tembhare, Constance Yuan, Neha Korde, Irina Maric, Ola Landgren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21942285      PMCID： PMC5571758          DOI： 10.3109/10428194.2011.623257

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  16 in total

1.  Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

Authors:  Michel de Weers; Yu-Tzu Tai; Michael S van der Veer; Joost M Bakker; Tom Vink; Daniëlle C H Jacobs; Lukas A Oomen; Matthias Peipp; Thomas Valerius; Jerry W Slootstra; Tuna Mutis; Wim K Bleeker; Kenneth C Anderson; Henk M Lokhorst; Jan G J van de Winkel; Paul W H I Parren
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

2.  Instability of immunophenotype in plasma cell myeloma.

Authors:  Wenqing Cao; Charles L Goolsby; Beverly P Nelson; Seema Singhal; Jayesh Mehta; Loann C Peterson
Journal:  Am J Clin Pathol       Date:  2008-06       Impact factor: 2.493

Review 3.  CD38: a new paradigm in lymphocyte activation and signal transduction.

Authors:  F E Lund; D A Cockayne; T D Randall; N Solvason; F Schuber; M C Howard
Journal:  Immunol Rev       Date:  1998-02       Impact factor: 12.988

4.  Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.

Authors:  K Detweiler Short; S V Rajkumar; D Larson; F Buadi; S Hayman; A Dispenzieri; M Gertz; S Kumar; J Mikhael; V Roy; R A Kyle; M Q Lacy
Journal:  Leukemia       Date:  2011-02-25       Impact factor: 11.528

Review 5.  Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.

Authors:  Karthick R M Raja; Lucie Kovarova; Roman Hajek
Journal:  Br J Haematol       Date:  2010-03-01       Impact factor: 6.998

6.  Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection.

Authors:  Mikhail Roshal; Jonathan R Fromm; Stuart Winter; Kimberly Dunsmore; Brent L Wood
Journal:  Cytometry B Clin Cytom       Date:  2010-05       Impact factor: 3.058

7.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

8.  Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.

Authors:  Pei Lin; Rebecca Owens; Guido Tricot; Carla S Wilson
Journal:  Am J Clin Pathol       Date:  2004-04       Impact factor: 2.493

9.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

10.  Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.

Authors:  Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544
View more
  5 in total

Review 1.  Immunotherapies targeting CD38 in Multiple Myeloma.

Authors:  Djordje Atanackovic; Mary Steinbach; Sabarinath Venniyil Radhakrishnan; Tim Luetkens
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

2.  p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain).

Authors:  Phaik Ju Teoh; Omer An; Tae-Hoon Chung; Thamil Vaiyapuri; Anandhkumar Raju; Michal M Hoppe; Sabrina H M Toh; Wilson Wang; Ming Chun Chan; Melissa J Fullwood; Anand D Jeyasekharan; Vinay Tergaonkar; Leilei Chen; Henry Yang; Wee Joo Chng
Journal:  Oncogene       Date:  2022-02-21       Impact factor: 8.756

Review 3.  Immunologic approaches for the treatment of multiple myeloma.

Authors:  Leo Rasche; Niels Weinhold; Gareth J Morgan; Frits van Rhee; Faith E Davies
Journal:  Cancer Treat Rev       Date:  2017-04-06       Impact factor: 12.111

Review 4.  CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Authors:  Arnab Ghosh; Sham Mailankody; Sergio A Giralt; C Ola Landgren; Eric L Smith; Renier J Brentjens
Journal:  Leuk Lymphoma       Date:  2017-11-06

5.  Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.

Authors:  Estefanía García-Guerrero; Ralph Götz; Sören Doose; Markus Sauer; Alfonso Rodríguez-Gil; Thomas Nerreter; K Martin Kortüm; José A Pérez-Simón; Hermann Einsele; Michael Hudecek; Sophia Danhof
Journal:  Leukemia       Date:  2020-04-29       Impact factor: 11.528
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.